A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's ...

Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...

The Lancet Diabetes & Endocrinology Commission on Diagnostic Criteria of Clinical Obesity will soon unveil a new ...

Maryland’s Medicaid program now offers partial coverage of popular obesity drugs, with the state spending more than $68 ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications to ...

The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.

Study authors point to semaglutide medication and “behavior changes” as possible reasons for the drop in obesity rates in the ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.